Cancer drug resistance: an evolving paradigm
The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10,11].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [10]
In the citing paper
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistance across KRAS mutant cancers.57,58”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Self-citationNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Cited by
Items 901–1,000 of 1,016
ACP-DA: Improving the Prediction of Anticancer Peptides Using Data Augmentation
Chen, X.-G., Zhang, W., Yang, X., Li, C., & Chen, H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.698477 · Cited by 72
“Although traditional anticancer drugs are effective, their shortcomings, such as gastrointestinal damage (Mitchell, 2006), are also notable and can easily cause multidrug tumor resistance (Holohan et al., 2013; Wijdeven et al., 2016).”
BackgroundGupta, P. K., Saraff, M., Gahtori, R., Negi, N., Tripathi, S. K., Kumar, J., Kumar, S., Aldhayan, S. H. A., Dhanasekaran, S., Abomughaid, M. M., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14070676 · Cited by 73
Pyroptosis Provides New Strategies for the Treatment of Cancer
Jia, Y., Wang, X., Deng, Y., Li, S., Xu, X., Qin, Y., & Peng, L. J. (2023) · Journal of Cancer · doi:10.7150/jca.77965 · Cited by 73
“For decades, apoptosis has been the main mode of cell death studied by people, but the failure to induce apoptosis is the main reason for failure of cancer treatment [10].”
BackgroundZhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 80
“However, drug resistance and adverse events are always major concerns for this type of treatment [317, 318].”
BackgroundProfiling single cancer cell metabolism via high-content SRS imaging with chemical sparsity
Tan, Y., Lin, H., & Cheng, J. (2023) · Science Advances · doi:10.1126/sciadv.adg6061 · Cited by 73
Role of Oxidative Stress in the Occurrence, Development, and Treatment of Breast Cancer
Dong, R., Wang, J., Guan, R., Sun, J., Jin, P., & Shen, J. (2025) · Antioxidants · doi:10.3390/antiox14010104 · Cited by 78
“This acquired drug resistance is often linked to modifications in the TME, alterations in intracellular metabolisms, and changes in gene expression [158,159].”
Chen, P., Qiu, M., Deng, C., Meng, F., Zhang, J., Cheng, R., & Zhong, Z. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00113 · Cited by 72
Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway
Tsai, H.-H., Lai, H.-Y., Chen, Y.-C., Li, C.-F., Huang, H.-S., Liu, H.-S., Tsai, Y.-S., & Wang, J.-M. (2017) · Oncotarget · doi:10.18632/oncotarget.14640 · Cited by 67
“Many cancers develop resistance to chemotherapy drugs under single treatment, which is a major factor in the failure of many forms of chemotherapy [41].”
BackgroundPandey, P. R., Chatterjee, B., Olanich, M. E., Khan, J. I., Miettinen, M., Hewitt, S. M., & Barr, F. G. (2017) · The Journal of Pathology · doi:10.1002/path.4867 · Cited by 72
“Some resistance mechanisms involve genetic alterations, such as point mutation or amplification in the oncoprotein, whereas other resistance mechanisms involve acquisition of alternative oncogenic pathways in tumour cells [30,31].”
BackgroundZhong, C., Chen, F., Yang, J., Jia, W., Li, L., Cheng, C., Du, F., Zhang, S., Xie, C., Zhang, N., et al. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.199 · Cited by 69
Xu, M., Seas, A., Kiyani, M., Ji, K. S. Y., & Bell, H. N. (2018) · Cell & Bioscience · doi:10.1186/s13578-018-0223-5 · Cited by 66
“P-glycoprotein or multidrug resistance protein 1 (MDR1), an ATP-dependent efflux pump that expels cytotoxic drugs, has also been associated with chemotherapeutic resistance in breast cancer [75].”
BackgroundChen, J., Sun, W., Zhang, H., Ma, J., Xu, P., Yu, Y., Fang, H., Zhou, L., Lv, J., Xie, J., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0313-2 · Cited by 72
Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer
Oatman, N., Dasgupta, N., Arora, P., Choi, K., Gawali, M. V., Gupta, N., Parameswaran, S., Salomone, J. R., Reisz, J. A., Lawler, S. E., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd7459 · Cited by 69
“Drug resistance is the underlying principle for cancer cell survival, tumor recurrence, and therapeutic failure ( 58 ).”
BackgroundDiener, J., & Sommer, L. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0351 · Cited by 64
Cheng, H., Fan, X., Wang, X., Ye, E., Loh, X. J., Li, Z., & Wu, Y.-L. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.7b01693 · Cited by 64
FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
Richtmann, S., Wilkens, D., Warth, A., Lasitschka, F., Winter, H., Christopoulos, P., Herth, F. J. F., Muley, T., Meister, M. A., & Schneider, M. A. (2019) · Cancers · doi:10.3390/cancers11050652 · Cited by 65
“cancer cells and multiple regulatory feedback loops resulting in therapy resistance [6].”
Ma, L., Wang, Z., Xie, M., Quan, Y., Zhu, W., Yang, F., Zhao, C., Fan, Y. J., Fang, N., Jiang, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2352-0 · Cited by 67
Wang, C., Zhou, Z., Subhramanyam, C. S., Cao, Q., Heng, Z. S., Liu, W., Fu, X., & Hu, Q. (2020) · Communications Biology · doi:10.1038/s42003-020-0983-4 · Cited by 71
Morosi, L., Meroni, M., Ubezio, P., Nerini, I. F., Minoli, L., Porcu, L., Panini, N., Colombo, M., Blouw, B., Kang, D. W., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02070-x · Cited by 66
Jiang, A., Zhou, Y., Gong, W., Pan, X. H., Gan, X., Wu, Z., Liu, B., Qu, L., & Wang, L. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5910575 · Cited by 75
“The application of targeted drugs has offered relatively good oncological outcomes in some tumors, but a considerable number of patients have innate drug resistance (DR) or develop DR after receiving treatment for a certain period [4, 5].”
Antitumor activity of an anti‐ CD 98 antibody
Hayes, G. M., Chinn, L., Cantor, J. M., Cairns, B., Levashova, Z. B., Tran, H., Velilla, T., Duey, D. Y., Lippincott, J., Zachwieja, J., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29415 · Cited by 72
“Because drug resistance mechanisms in cancer treatment lead to poor patient outcomes, targeting several orthogonal pathways with different drugs or using a drug with multiple mechanisms of action may delay or overcome drug resistance.(29) Therapeutic anti-CD20 antibodies, such as rituximab and obinutuzumab, elicit ADC…”
BackgroundE3 Ubiquitin Ligase HOIP Attenuates Apoptotic Cell Death Induced by Cisplatin
MacKay, C., Carroll, E., Ibrahim, A. F. M., Garg, A. K., Inman, G. J., Hay, R. T., & Alpi, A. F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2131 · Cited by 67
Taccioli, C., Sorrentino, G., Zannini, A., Caroli, J., Beneventano, D., Anderlucci, L., Lolli, M., Bicciato, S., & Del Sal, G. (2015) · Oncotarget · doi:10.18632/oncotarget.5749 · Cited by 64
“com/oncotarget benefit of such therapeutic intervention, tumours often recur in few months due to acquired drug resistance, which calls for urgent development of novel strategies to identify drugs for personalized therapies [41].”
BackgroundEngineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors
Ham, S. L., Joshi, R., Luker, G. D., & Tavana, H. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600644 · Cited by 64
Hou, G., Yuan, X., Li, Y., Hou, G., & Liu, X. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00781-9 · Cited by 70
EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo
Chen, L., He, J., Zhou, J., Xiao, Z. Q., Ding, N., Duan, Y., Li, W., & Sun, L. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14469 · Cited by 73
Huang, P., Wang, G., Su, Y., Zhou, Y., Huang, W., Zhang, R., & Yan, D. (2019) · Theranostics · doi:10.7150/thno.36163 · Cited by 65
“, out of the cancer cells to decrease their intracellular accumulation dramatically, which results in the lower therapeutic efficacy [2-4].”
BackgroundNon-Apoptotic Cell Death Signaling Pathways in Melanoma
Hartman, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082980 · Cited by 74
“For decades, apoptosis has been investigated as a major RCD modality involved in the survival of cancer cells and their response to anti-cancer drugs [9].”
BackgroundAdaptive response of resistant cancer cells to chemotherapy
Chern, Y., & Tai, I. T. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0005 · Cited by 77
Liu, X., Yang, J., Zhang, Y., Fang, Y., Wang, F., Wang, J., Zheng, X., & Yang, J. (2016) · Scientific Reports · doi:10.1038/srep22811 · Cited by 63
“…blank in the table represents the drugs with the small numbers of DRA genes ( ≤ 20) and higher false positive rates judged by the permutation test. breast cancer resistance protein (BCRP; also known as ABCG2) are known to cause resistance in common chem-otherapeutics by promoting drug efflux 31 .”
BackgroundNanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant
Liang, Y., Liu, Z.-Y., Wang, P., Li, Y., Wang, R., & Xie, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.034 · Cited by 65
The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting
Sun, M., Wang, T., Li, L., Li, X., Zhai, Y., Zhang, J., & Li, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.702445 · Cited by 74
“Drug resistance is another common problem in the treatment of EGFR-targeted drugs, such as the changes of miRNA and gene profiles (Holohan et al., 2013).”
BackgroundDrug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
Ajmeera, D., & Ajumeera, R. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.12.013 · Cited by 68
“Other genetic alterations, such as chromosomal rearrangements and mutations in anaplastic lymphoma kinase, are seen in anaplastic large-cell lymphoma.(86,87)”
BackgroundTherapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Ye, J., Wu, J., & Liu, B. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188866 · Cited by 70
Tabolacci, C., Cordella, M., Turcano, L., Rossi, S., Lentini, A., Mariotti, S., Nisini, R., Sette, G., Eramo, A., Piredda, L., et al. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.057 · Cited by 64
“subpopulation of CSCs present in the original tumor (Holohan et al., 2013; Cojoc et al., 2015).”
BackgroundSun, H., Cheng, R., Deng, C., Meng, F., Dias, A. A., Hendriks, M., Feijén, J., & Zhong, Z. (2015) · Biomacromolecules · doi:10.1021/bm501652d · Cited by 65
Cheeseman, M. D., Chessum, N. E. A., Rye, C. S., Pasqua, E., Tucker, M. J., Wilding, B., Evans, L. E., Lepri, S., Richards, M., Sharp, S. Y., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01055 · Cited by 66
Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia
Campbell, C. T., Haladyna, J. N., Drubin, D. A., Thomson, T. M., Maria, M. J., Yamauchi, T., Waters, N. J., Olhava, E. J., Pollock, R. M., Smith, J. J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0693 · Cited by 73
“Resistance has been reported to occur through multiple mechanisms such as transformation of the drug target through genetic variation (indels or single base modifications), overexpression, and alternative signal transduction (28).”
BackgroundExosomal microRNA: a Novel Biomarker for Breast Cancer
He, Y., Deng, F., Yang, S., Wang, D., Chen, X., Zhong, S., Zhao, J., & Tang, J. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0305 · Cited by 68
Moreira‐Pais, A., Ferreira, R. M., & da Costa, R. M. G. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.010 · Cited by 73
Yin, P. T., Pongkulapa, T., Cho, H., Han, J., Pasquale, N. J., Rabie, H., Kim, J., Choi, J., & Lee, K. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b09086 · Cited by 64
Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it
Verma, H., Bahia, M. S., Choudhary, S., Singh, P. K., & Silakari, O. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1632886 · Cited by 69
“The selective inhibition of DMEs would help to improve the bioavailability of available chemoagents and reverse drug resistance.”
BackgroundInfluentialTargeting cellular cholesterol for anticancer therapy
Gu, L., Saha, S. T., Thomas, J., & Kaur, M. (2019) · FEBS Journal · doi:10.1111/febs.15018 · Cited by 71
Hamasy, A., Wang, Q., Blomberg, K. E. M., Mohammad, D. K., Yu, L., Vihinen, M., Berglöf, A., & Smith, C. I. E. (2017) · Leukemia · doi:10.1038/leu.2016.153 · Cited by 62
Siu, M. K., Abou-Kheir, W., Yin, J. J., Chang, Y.-S., Barrett, B., Suau, F., Casey, O., Chen, W.-Y., Fang, L., Hynes, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1994 · Cited by 62
Contribution of Epithelial Plasticity to Therapy Resistance
Santamaría, P. G., Moreno‐Bueno, G., & Cano, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050676 · Cited by 69
Natural Product Target Network Reveals Potential for Cancer Combination Therapies
Chamberlin, S. R., Blucher, A., Wu, G., Shinto, L. H., Choonoo, G., Kulesz-Martin, M. F., & McWeeney, S. K. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00557 · Cited by 66
“In cancer, these mechanisms can include compensatory and redundant molecular signaling, target mutations acquired during treatment, increased expression of the targeted proteins, inactivation of pro-apoptotic pathways, inhibition of DNA repair mechanisms, epithelial-mesenchymal transition, activation of pro-survival s…”
BackgroundImplications of Enhancer Transcription and eRNAs in Cancer
Adhikary, S., Roy, S., Chacon, J. A., Gadad, S. S., & Das, C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4010 · Cited by 70
Yuan, S., Wang, B., Dai, Q.-Q., Zhang, X., Zhang, J., Zuo, J.-H., Liu, H., Chen, Z., Li, G., Wang, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01452 · Cited by 64
RNF8 Promotes Lung Cancer Tumorigenesis and Chemoresistance by Regulating AKT
Xu, Y., Hu, Y., Xu, T., Yan, K., Zhang, T., Li, Q., Chang, F., Guo, X., Peng, J., Li, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109854 · Cited by 63
Mendoza, E. N., Ciriolo, M. R., & Ciccarone, F. (2025) · Antioxidants · doi:10.3390/antiox14010094 · Cited by 74
“This system is particularly effective in maintaining the survival of cancer cells in the face of chemotherapeutic stress, making it a major contributor to treatment failure [50].”
The molecular mechanisms underlying the therapeutic resistance of cancer stem cells
Kim, J.-K., Jeon, H.-Y., & Kim, H. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0531-1 · Cited by 64
“Among the 49 ABC transporters in humans, only three have been largely studied in multi-drug resistance of cancers (Fletcher et al. 2010; Holohan et al. 2013): ABCB1 (Multi-drug resistance protein 1; MDR1/P-glycoprotein), ABCC1 (MDR-associ- ated protein1/MRP1), and ABCG2 (BCRP).”
BackgroundInfluentialCaveolin-1, a stress-related oncotarget, in drug resistance
Wang, Z., Wang, N., Liu, P., Peng, F., Tang, H., Chen, Q., Xu, R., Dai, Y., Lin, Y. H., Xie, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5789 · Cited by 70
“Currently three major mechanisms of MDR have been proposed: decreased chemotherapeutic uptake, absorption and distribution; aberrant drug metabolism that diminishes therapeutic efficacy, such as target alterations, DNA damage repair and cell death signaling pathway dysregulation; and finally, increased energy-dependen…”
BackgroundChoe, C., Shin, Y.-S., Choi, S.-J., Lee, J., Kim, S., Cho, Y. B., Kim, J., & Kim, C. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89659 · Cited by 62
“Discussion A major shift in the paradigm of drug development targeting the recurrence of primary tumors following treatment with targeted kinase inhibitors is to prevent or delay their acquired resistance through regulation of normal tissue homeostasis and architecture.(23) In this study, we have shown that crosstalk…”
BackgroundWang, M., Shen, A., Zhang, C., Song, Z., Ai, J., Liu, H., Sun, L., Ding, J., Geng, M., & Zhang, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01106 · Cited by 62
Wu, Q., Sharma, S., Cui, H., LeBlanc, S. E., Zhang, H., Muthuswami, R., Nickerson, J. A., & Imbalzano, A. N. (2016) · Oncotarget · doi:10.18632/oncotarget.8384 · Cited by 67
“One common reason for resistance to multiple anticancer drugs is the increased expression of one or more energy-dependent transporters that result in efflux of the drugs from cells [11, 12].”
Was, H., Barszcz, K., Czarnecka, J., Kowalczyk, A., Bernas, T., Uzarowska, E., Koza, P., Klejman, A., Piwocka, K., Kaminska, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14066 · Cited by 61
Billington, S. F., Ray, A. S., Salphati, L., Xiao, G., Chu, X., Humphreys, W. G., Liao, M., Lee, C. A., Mathias, A. A., Hop, C. E. C. A., et al. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.077289 · Cited by 66
“Such resistance can be conferred by various mechanisms such as: 1) reduced uptake of the drug into the target cells; 2) alterations within the cells such as altered metabolism, an increased capacity to repair DNA or reduced apoptosis; and 3) an increased efflux of the drug from the target cells (Holohan et al., 2013).”
Zhang, Q., Zhang, B., Sun, L., Yan, Q., Zhang, Y., Zhang, Z., Su, Y., & Wang, C. (2018) · Cell Biochemistry and Function · doi:10.1002/cbf.3331 · Cited by 72
Treatment resistance in urothelial carcinoma: an evolutionary perspective
Vlachostergios, P. J., & Faltas, B. M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0026-y · Cited by 64
Li, L., Pan, D., Chen, Q., Zhang, S.-W., Xie, D., Zheng, X., & Chen, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490871 · Cited by 65
SET Domain–Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence
Ye, S., Ding, Y.-F., Jia, W.-H., Liu, X., Feng, J., Zhu, Q., Cai, S.-L., Yang, Y.-S., Lu, Q.-Y., Huang, X.-T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1084 · Cited by 65
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistanceacrossKRASmutant cancers.(57,58) For example, the expression of select HER (human epidermal growth factor receptor)”
InfluentialTargeting SphK2 reverses acquired resistance of Regorafenib in hepatocellular carcinoma
Shi, W., Zhang, S., Ma, D., Yan, D., Zhang, G., Cao, Y., Wang, Z., Wu, J., & Jiang, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00694 · Cited by 61
Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer
Cunningham, J. J., Thuijsman, F., Peeters, R., Viossat, Y., Brown, J. S., Gatenby, R. A., & Staňková, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243386 · Cited by 66
Recent advances in enhancing reactive oxygen species based chemodynamic therapy
Li, X., Luo, R., Liang, X., Wu, Q., & Gong, C. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.11.048 · Cited by 62
Interference of layered double hydroxide nanoparticles with pathways for biomedical applications
Jing, G., Yang, L., Wang, H., Niu, J., Li, Y., & Wang, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114451 · Cited by 65
The value of monitoring to control evolving populations
Fischer, A., Vázquez-Garćıa, I., & Mustonen, V. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409403112 · Cited by 71
“There are very few cases where the genetic basis for a drug-resistance mechanism is known and can be specifically monitored [33, 34].”
Backgroundde Melo‐Diogo, D., Gaspar, V. M., Costa, E. C., Moreira, A. F., Oppolzer, D., Gallardo, E., & Correia, I. J. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.09.013 · Cited by 62
Harazono, Y., Kho, D. H., Balan, V., Nakajima, K., Zhang, T., Hogan, V. A., & Raz, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2486 · Cited by 61
“Since Bcl-2 family consists of many members and expresses in cell-type specific fashion [4], further studies will be needed to define the role of Gal-3 using constructs of these Bcl-2 members.”
BackgroundInfluentialChang, C., Wang, Y., Zalath, M. B., Liu, D., Cardillo, T. M., & Goldenberg, D. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0219 · Cited by 62
Zhu, W.-J., Yang, S.-D., Qu, C., Zhu, Q., Chen, W.-L., Li, F., Yuan, Z.-Q., Liu, Y., You, B., & Zhang, X. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s126310 · Cited by 62
“1,2 MDR is caused by the overexpression of multiple efflux transport proteins, including ATP-binding cassette (ABC) transporters, 3 which operate as exporters in cells and hydrolyze ATP to yield the energy necessary for transport.”
BackgroundLang, J., Zhao, X., Wang, X., Zhao, Y., Li, Y., Zhao, R., Cheng, K., Li, Y., Han, X., Zheng, X., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b08823 · Cited by 89
An azo dye for photodynamic therapy that is activated selectively by two-photon excitation
Juvekar, V., Lim, C. S., Lee, D. J., Park, S. J., Song, G. O., Kang, H., & Kim, H. M. (2020) · Chemical Science · doi:10.1039/d0sc05686c · Cited by 62
Therapeutic Potential of Ursonic Acid: Comparison with Ursolic Acid
Son, J., & Lee, S. Y. (2020) · Biomolecules · doi:10.3390/biom10111505 · Cited by 66
“Various cellular mechanisms of resistance to existing anticancer agents disrupt the efficacy of modern chemotherapy, indicating that development of new bioactive molecules is needed to solve this problem [44].”
BackgroundRecent advances in covalent organic frameworks for cancer diagnosis and therapy
Bagheri, A. R., Li, C., Zhang, X., Zhou, X., Aramesh, N., Zhou, H., & Jia, J. (2021) · Biomaterials Science · doi:10.1039/d1bm00960e · Cited by 62
Oliveras‐Ferraros, C., Vázquez‐Martín, A., Cuyàs, E., Corominas-Faja, B., Rodríguez‐Gallego, E., Fernández‐Arroyo, S., Martín-Castillo, B., Joven, J., & Menéndez, J. A. (2014) · Cell Cycle · doi:10.4161/cc.27982 · Cited by 66
“2) were related to: (1) Connective tissue disorders, dermatological diseases and conditions, developmental disorder (score = 41), including the cancer stem cell marker DCLK1, the enhancer of the cell motility and metastasis BCAR3 (breast cancer antiestrogen resistance 3) gene, and the PABPC1 (poly A binding protein 1)…”
BackgroundThe emerging molecular machinery and therapeutic targets of metastasis
Sun, Y., & Ma, L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.001 · Cited by 64
“CSCs are also believed to be resistant to chemotherapy due to high expression or activation of ATP-binding cassette (ABC) transporter proteins, aldehyde dehydrogenase (ALDH), antiapoptotic proteins, pro-survival signaling components, and DNA repair molecules [108].”
BackgroundXu, L., Gao, C., Wu, Y., Cheng, C. Y., Xia, W., & Zhang, Z. (2015) · Journal of Materials Chemistry B · doi:10.1039/c4tb01764a · Cited by 61
Seebacher, N. A., Lane, D. J. R., Jansson, P. J., & Richardson, D. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.682450 · Cited by 64
“Multidrug resistance (MDR)(5) is the principal cause of cancer cell resistance to chemotherapeutic drug treatment (1, 2).”
BackgroundGhosh, R. D., Ghuwalewala, S., Das, P. K., Mandloi, S., Alam, S. K., Chakraborty, J., Sarkar, S., Chakrabarti, S., Panda, C. K., & Roychoudhury, S. (2016) · Scientific Reports · doi:10.1038/srep23932 · Cited by 64
Lu, C.-S., Shieh, G.-S., Wang, C.-T., Su, B., Su, Y., Chen, Y.-C., Su, W., Wu, P., Yang, W., Shiau, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9602 · Cited by 66
“com/oncotarget cellular uptake, increased efflux, increased DNA repair, and hypermethylation of the MLH1 gene, a mismatch repair gene [19].”
BackgroundA Place for Precision Medicine in Bladder Cancer: Targeting the Fgfrs
di Martino, E., Tomlinson, D. C., Williams, S. V., & Knowles, M. A. (2016) · Future Oncology · doi:10.2217/fon-2016-0042 · Cited by 63
Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism
Ullah, M., Akbar, A., Ng, N. N., Concepcion, W., & Thakor, A. S. (2019) · Oncotarget · doi:10.18632/oncotarget.26952 · Cited by 62
“In addition, there was also a CD9 dependent increase in MDR1 and BCRP; both of which are ABC transporters that have been shown in other cancer models to confer multidrug resistance to chemotherapies such as Dox and 5FU [40, 41].”
BackgroundDahiya, R., Mohammad, T., Gupta, P., Haque, A., Alajmi, M. F., Hussain, A., & Hassan, M. I. (2019) · RSC Advances · doi:10.1039/c9ra02864a · Cited by 63
In silico design and optimization of selective membranolytic anticancer peptides
Gabernet, G., Gautschi, D., Müller, A. T., Neuhaus, C. S., Armbrecht, L., Dittrich, P. S., Hiss, J. A., & Schneider, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-47568-9 · Cited by 61
ZEB1: New advances in fibrosis and cancer
Cheng, L., Zhou, M., Gu, Y., Chen, L., & Wang, Y. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-04036-7 · Cited by 76
Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer
Chun, K., Park, J. H., & Fan, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_4 · Cited by 64
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer
Rudalska, R., Harbig, J., Snaebjornsson, M. T., Klotz, S., Zwirner, S., Taranets, L., Heinzmann, F., Kronenberger, T., Förster, M., Cui, W., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00168-3 · Cited by 67
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview
Argentiero, A., Solimando, A. G., Brunetti, O., Calabrese, A., Pantano, F., Iuliani, M., Santini, D., Silvestris, N., & Vacca, A. (2019) · Cancers · doi:10.3390/cancers11091270 · Cited by 60
“[37,38] Therefore, a number of molecular actors”
Battista, T., Fiorillo, A., Chiarini, V., Genovese, I., Ilari, A., & Colotti, G. (2020) · Cancers · doi:10.3390/cancers12040887 · Cited by 62
“Many mechanisms operate to confer drug resistance (Figure 1) [97]: scarce drug solubility and toxicity to normal tissues limit the doses of chemotherapeutic drugs that can be administered to cancer patients; pharmacokinetic issues, as absorption, distribution, metabolism, and elimination, reduce the amount of chemothe…”
BackgroundAhmad, I. I., Fakhri, S., Khan, H. Z., Jeandet, P., Aschner, M., & Yu, Z. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109229 · Cited by 67
Targeting Ubiquitin-Specific Protease 7 (USP7) in Cancer: A New Insight to Overcome Drug Resistance
Lu, J., Zhao, H., Yu, C., Kang, Y., & Yang, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648491 · Cited by 70
“However, clinically there are still phenomena such as poor efficacy, tumor recurrence, metastasis, and drug resistance remain (Holohan et al., 2013; Quail and Joyce, 2013; Mahvi et al., 2018).”
BackgroundFerroptosis: The Silver Lining of Cancer Therapy
Tang, Z., Huang, Z., Huang, Y., Chen, Y., Huang, M., Liu, H., Ye, Q. A., Zhao, J., & Jia, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.765859 · Cited by 66
“FSP1 was previously known as apoptosisinducing factor mitochondrial 2 (AIFM2) and has significant homology to apoptosis-inducing factor (AIF) (Wu et al., 2002), a flavoprotein described initially as a P53-responsive gene (Horikoshi et al., 1999) that induces apoptosis.”
BackgroundSelf-assembled nanoformulations of paclitaxel for enhanced cancer theranostics
Pei, Q., Jiang, B., Hao, D., & Xie, Z. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.021 · Cited by 64
2-Aminobenzothiazoles in anticancer drug design and discovery
Huang, G., Cierpicki, T., & Grembecka, J. E. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106477 · Cited by 68
Barbieri, F., Thellung, S., Ratto, A., Carra, E., Marini, V., Fucile, C., Bajetto, A., Pattarozzi, A., Würth, R., Gatti, M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1235-8 · Cited by 58
“These cells exhibit stem-like features, such as self-renewal, differentiation capacity, and are believed to represent the subpopulation responsible for the tumor-initiating activity and the resistance to antineoplastic agents [2,3].”
BackgroundShen, A., Wang, L., Huang, M., Sun, J., Chen, Y., Shen, Y., Yang, X., Wang, X., Ding, J., & Geng, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2743 · Cited by 65
Guestini, F., McNamara, K. M., Ishida, T., & Sasano, H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125469 · Cited by 58
“can even demonstrate a cross-resistance to other therapeutic agents.[2] Due to the inherit diversity, the prediction of treatment response should serve as a”
BackgroundThe Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58
Metadata
- Authors
- Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 714-726
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042619042
- Cited by
- 4,681
- References
- 178
- Citations by year
- 2026: 322 · 2025: 358 · 2024: 327 · 2023: 356 · 2022: 364 · 2021: 442 · 2020: 465 · 2019: 460 · 2018: 433 · 2017: 385 · 2016: 342 · 2015: 276 · 2014: 135 · 2013: 4
- FWCI
- 26.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Cancer Research UK (13172, 13721, C212/A13721)
- Public Health Agency (RRG/3261/05)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- chemoresistance, targeted therapy, drug target alterations, cell death evasion, predictive biomarkers, patient stratification, high-throughput screening, preclinical models
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, Autophagy, Biological Transport, Biotransformation, DNA Damage, DNA Repair, Humans, Models, Biological, Mutation, Neoplasm Proteins, Neoplastic Stem Cells, Drug Design, Gene Expression Regulation, Neoplastic, Apoptosis, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Gene Silencing, Apoptosis Regulatory Proteins, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.